Reassessment of idoxuridine therapy of herpetic keratitis.
D002986:Clinical Trials as Topic; D003231:Conjunctivitis / Q000139:chemically induced; D003320:Corneal Ulcer / Q000139:chemically induced / Q000188:drug therapy; D003877:Dermatitis, Contact / Q000209:etiology; D005141:Eyelid Diseases / Q000139:chemically induced; D006801:Humans; D007065:Idoxuridine / Q000009:adverse effects / Q000627:therapeutic use*; D007634:Keratitis / Q000139:chemically induced; D007635:Keratitis, Dendritic / Q000188:drug therapy*; D010919:Placebos; D011370:Proflavine / Q000627:therapeutic use; D012008:Recurrence; D012636:Secretory Rate / Q000187:drug effects; D013666:Tears / Q000378:metabolism; D014740:Vidarabine / Q000627:therapeutic use
D010919:Placebos; D011370:Proflavine; D014740:Vidarabine; D007065:Idoxuridine